These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26351466)

  • 1. Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program.
    Lee PA; Ross JL; Pedersen BT; Kotnik P; Germak JA; Christesen HT
    Int J Pediatr Endocrinol; 2015; 2015(1):17. PubMed ID: 26351466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis.
    Ross J; Fridman M; Kelepouris N; Murray K; Krone N; Polak M; Rohrer TR; Pietropoli A; Lawrence N; Backeljauw P
    J Endocr Soc; 2023 Mar; 7(5):bvad026. PubMed ID: 36936713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry.
    Lee PA; Ross J; Germak JA; Gut R
    Int J Pediatr Endocrinol; 2012 Jun; 2012(1):15. PubMed ID: 22682146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age and duration of growth hormone therapy in children with Turner syndrome.
    Ross J; Lee PA; Gut R; Germak J
    Horm Res Paediatr; 2011; 76(6):392-9. PubMed ID: 22156541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program.
    Backeljauw P; Blair JC; Ferran JM; Kelepouris N; Miller BS; Pietropoli A; Polak M; Sävendahl L; Verlinde F; Rohrer TR
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2653-2665. PubMed ID: 36947589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome.
    Rohrer TR; Abuzzahab J; Backeljauw P; Birkegård AC; Blair J; Dahlgren J; Júlíusson PB; Ostrow V; Pietropoli A; Polak M; Romano A; Ross J; Sävendahl L; Miller BS
    Horm Res Paediatr; 2020; 93(6):380-395. PubMed ID: 33440388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study.
    Ross J; Lee PA; Gut R; Germak J
    Int J Pediatr Endocrinol; 2010; 2010():494656. PubMed ID: 20981140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program.
    Sävendahl L; Polak M; Backeljauw P; Blair J; Miller BS; Rohrer TR; Pietropoli A; Ostrow V; Ross J
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4730-4742. PubMed ID: 31305924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program.
    Ross JL; Lee PA; Gut R; Germak J
    Int J Pediatr Endocrinol; 2015; 2015(1):1. PubMed ID: 25904938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.
    Lee PA; Germak J; Gut R; Khutoryansky N; Ross J
    Int J Pediatr Endocrinol; 2011 Jul; 2011(1):6. PubMed ID: 21899782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome.
    Dahlgren J; Albertsson-Wikland K
    Front Endocrinol (Lausanne); 2021; 12():737893. PubMed ID: 34858328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study.
    Angulo M; Abuzzahab MJ; Pietropoli A; Ostrow V; Kelepouris N; Tauber M
    Int J Pediatr Endocrinol; 2020 Nov; 2020(1):20. PubMed ID: 33292530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender influences short-term growth hormone treatment response in children.
    Sävendahl L; Blankenstein O; Oliver I; Christesen HT; Lee P; Pedersen BT; Rakov V; Ross J
    Horm Res Paediatr; 2012; 77(3):188-94. PubMed ID: 22508317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study.
    Blankenstein O; Snajderova M; Blair J; Pournara E; Pedersen BT; Petit IO
    Eur J Endocrinol; 2017 Aug; 177(2):145-155. PubMed ID: 28522645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program.
    Biller BMK; Höybye C; Carroll P; Gordon MB; Birkegård AC; Kelepouris N; Nedjatian N; Weber MM
    Pituitary; 2021 Aug; 24(4):611-621. PubMed ID: 33709288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short Stature: Comparison of WHO and National Growth Standards/References for Height.
    Christesen HT; Pedersen BT; Pournara E; Petit IO; Júlíusson PB
    PLoS One; 2016; 11(6):e0157277. PubMed ID: 27280591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.
    Romano AA; Dana K; Bakker B; Davis DA; Hunold JJ; Jacobs J; Lippe B
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2338-44. PubMed ID: 19401366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®).
    Höybye C; Sävendahl L; Christesen HT; Lee P; Pedersen BT; Schlumpf M; Germak J; Ross J
    Clin Epidemiol; 2013; 5():119-27. PubMed ID: 23658497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Pfäffle RW; Höybye C; Lundberg E; Battelino T; Kriström B; Giemza T; Zouater H
    Horm Res Paediatr; 2021; 94(3-4):133-143. PubMed ID: 34350858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.